Different acute responses of serum type I collagen telopeptides, CTX, NTX and ICTP, after repeated ingestion of calcium.
BACKGROUND
N- and C-terminal fragments of type I collagen such as NTX, CTX and ICTP are released into circulation during bone resorption and can be quantified in serum. Their respective sensitivity as indices of osteoclastic activity was compared after a short-term inhibition of resorption induced by repeated drinking of calcium-fortified water.


METHODS
Serum NTX, CTX and ICTP were measured by specific immunoassays in one group of 15 subjects sampled at 08.00, 11.00, 14.00 and 17.00 (referred to as T0, T3h, T6h and T9h) and having ingested in two experimental periods 660 ml of either low-calcium mineral water or the same low-calcium mineral water fortified with calcium (300 mg/l) at three times (08.00, 11.00 and 14.00).


RESULTS
Oral intake of calcium-fortified water resulted in progressive decrease in serum CTX (by 38.7% at T3h, 61.0% at T6h and 60.4% at T9h) and NTX (by 19.0% at T3h, 24.1% at T6h and 25.2% at T9h) while serum ICTP concentrations were not significantly affected. Since ingestion of low-calcium water induced a modest but significant decrease in both CTX (-19.4%) and NTX (-10.6%) we compared the two sets of assays with repeated-measures two-factor analysis of variance with interaction. Ingestion of calcium-fortified water vs. low-calcium water resulted in a significant decrease in both serum CTX (time, P<0.0001; treatment, P<0.0001; time-by treatment, P<0.0001) and NTX (time, P<0.0001; treatment, P=0.0001; time-by treatment, P=0.0066).


CONCLUSIONS
CTX is more sensitive than NTX while ICTP is not sensitive to calcium-induced acute changes in osteoclastic activity. The present results stress the importance of choosing appropriate biochemical bone markers to demonstrate the effects of calcium on bone resorption.
Service de Biochimie Médicale, Faculté de Médecine Pitié-Salpêtrière, Paris, France.
Josette A
JA
Guillemant
Chantal M
CM
Accarie
Viviane
V
de la Gueronniere
Serge E
SE
Guillemant
D000284:Administration, Oral; D000328:Adult; D000704:Analysis of Variance; D015415:Biomarkers / Q000097:blood; D001862:Bone Resorption / Q000378:metabolism; D002118:Calcium / Q000097:blood / Q000494:pharmacology*; D003094:Collagen / Q000097:blood / Q000187:drug effects*; D024042:Collagen Type I / Q000378:metabolism; D006801:Humans; D007118:Immunoassay; D008297:Male; D010281:Parathyroid Hormone / Q000097:blood; D010455:Peptides / Q000097:blood / Q000187:drug effects*; D014867:Water / Q000737:chemistry / Q000494:pharmacology
D015415:Biomarkers; D024042:Collagen Type I; D010281:Parathyroid Hormone; D010455:Peptides; C052929:collagen type I trimeric cross-linked peptide; D014867:Water; D003094:Collagen; D002118:Calcium